The Immune-Mediated Inflammatory Diseases Market Size is estimated to grow at a 7.10% CAGR during the forecast period for 2024-2031.
Immune-mediated inflammatory disease (IMID) is refered as a collection of unrelated illnesses that have a common inflammatory pathway that causes inflammation but no clear etiology. Immune-mediated inflammatory diseases are disorders brought on by the immune system's excessive or aberrant activity. All immune-mediated inflammatory disorders (IMID) are linked to higher rates of morbidity and/or mortality, as well as the potential to harm organs. Worldwide, the number of people afflicted with autoimmune illnesses is steadily increasing. Many of these illnesses have underlying causes that might be linked to genetic predispositions, unhealthy eating patterns, and poor lifestyle choices. The market for immune-mediated inflammatory diseases is growing globally as the prevalence of these illnesses rises.
The need for immune-mediated inflammatory disease treatment has increased due to an increase in the frequency of chronic diseases of the liver, heart, kidneys, pancreas, and blood problems. The global market for immune-mediated inflammatory diseases is, therefore, driven by an increase in the prevalence of autoimmune diseases worldwide. However, during the projected time, it is expected that inadequate reimbursement, pharmacological side effects, and a lack of patient awareness will impede immune-mediated inflammatory disease market expansion.
The immune-mediated inflammatory diseases market is segmented based on indication, treatment type, indication, route of administration, end-user, and distribution channel. The indication segment is further segmented into Asthma, Chronic Obstructive Pulmonary Diseases (COPD), Inflammatory Bowel Disease (IBD), Systemic Lupus Erythematosus (SLE), Psoriasis, Rheumatoid Arthritis (RA), and Others. By treatment type, the market is segmented into Traditional Drugs, Biologic Therapies, and Novel Therapies. The route of administration segment includes Oral, Parenteral, and Others. As per the end-user, the market is segmented into Hospitals, Specialty Clinics, and Others. According to the distribution channel segment, the market is divided into Hospital Pharmacy, Retail Pharmacy, and Others.
The Rheumatoid Arthritis (RA) category is expected to lead with a significant market share, driven by improvements in targeted biologic therapy, growing prevalence rates, and growing awareness of early detection. The management of RA has changed as a result of the increasing use of biologics and disease-modifying antirheumatic medications (DMARDs), such as TNF inhibitors and interleukin blockers, which have improved patient outcomes. In order to meet unmet clinical needs, pharmaceutical companies are also concentrating on creating novel medicines, such as Janus kinase (JAK) inhibitors. Further driving market expansion includes the rising prevalence of RA, particularly in older populations, and supportive healthcare policies.
The hospitals held the largest share in the immune-mediated inflammatory diseases market. Hospitals are treating more patients with immune-mediated inflammatory diseases. A range of autoimmune disorders are treated using the medicines. The disease is effectively controlled by the medicines, and its advancement is halted. Furthermore, the therapies aid in enhancing the patients' quality of life.
The North American immune-mediated inflammatory diseases market is expected to note the highest market share in revenue in the near future due to the region's concentration of significant pharmaceutical companies and rising healthcare costs. The demand for novel treatments, the rising prevalence of autoimmune diseases, and the growing significance of targeted biologic therapy are all driving forces behind the immune-mediated inflammatory diseases market's growth. The market is also expected to be driven by the increasing number of novel therapeutic approvals and the rising demand for immunosuppressants in North America. In addition, Asia Pacific is predicted to grow rapidly in the global immune-mediated inflammatory diseases market as a result of increased awareness and information about this area. The immune-mediated inflammatory diseases market's expansion in this sector is also being fueled by more treatment options becoming available, an increase in the frequency of autoimmune diseases, and technological advancements in the management of immune-mediated inflammatory diseases.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 7.10% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Indication, Treatment Type, Indication, Route Of Administration, End-User, And Distribution Channel |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Novartis AG (Switzerland), Daiichi Sankyo Company, Limited (Japan), Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Merck & Co Inc. (U.S.), Zydus Group (India), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceuticals Industries Ltd. (Israel), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), AstraZeneca (U.K.), Ampio Pharmaceuticals Inc. (U.S.), Lilly (U.S), and Akorn, Incorporated (U.S.). |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Immune-Mediated Inflammatory Diseases Market By Indication-
Immune-Mediated Inflammatory Diseases Market By Treatment Type-
Immune-Mediated Inflammatory Diseases Market By Route of Administration-
Immune-Mediated Inflammatory Diseases Market By End-Users-
Immune-Mediated Inflammatory Diseases Market By Distribution Channel-
Immune-Mediated Inflammatory Diseases Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Immune-Mediated Inflammatory Diseases Market Snapshot
Chapter 4. Global Immune-Mediated Inflammatory Diseases Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Immune-Mediated Inflammatory Diseases Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Immune-Mediated Inflammatory Diseases Industry Trends
Chapter 5. Immune-Mediated Inflammatory Diseases Market Segmentation 1: By Indication, Estimates & Trend Analysis
5.1. Market Share by Indication, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Indication:
5.2.1. Asthma, Chronic Obstructive Pulmonary Diseases (COPD)
5.2.2. Inflammatory Bowel Disease (IBD)
5.2.3. Systemic Lupus Erythematosus (SLE)
5.2.4. Rheumatoid Arthritis (RA)
5.2.5. Psoriasis
5.2.6. Others
Chapter 6. Immune-Mediated Inflammatory Diseases Market Segmentation 2: By Treatment Type Area, Estimates & Trend Analysis
6.1. Market Share by Treatment Type Area, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Treatment Types Area:
6.2.1. Traditional Drugs
6.2.2. Biologic Therapies
6.2.3. Novel Therapies
Chapter 7. Immune-Mediated Inflammatory Diseases Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis
7.1. Market Share by Route of Administration, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administrations:
7.2.1. Oral
7.2.2. Parenteral
7.2.3. Others
Chapter 8. Immune-Mediated Inflammatory Diseases Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis
8.1. Market Share by Distribution Channel, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channels:
8.2.1. Hospital Pharmacy
8.2.2. Retail Pharmacy
8.2.3. Others
Chapter 9. Immune-Mediated Inflammatory Diseases Market Segmentation 5: By End User, Estimates & Trend Analysis
9.1. Market Share by End User, 2023 & 2031
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End Users:
9.2.1. Hospitals
9.2.2. Specialty Clinics
9.2.3. Others
Chapter 10. Immune-Mediated Inflammatory Diseases Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Immune-Mediated Inflammatory Diseases Market, Regional Snapshot 2023 & 2031
10.2. North America
10.2.1. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
10.2.3. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031
10.2.4. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.2.5. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.2.6. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
10.3. Europe
10.3.1. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
10.3.3. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031
10.3.4. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.3.5. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.3.6. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
10.4. Asia Pacific
10.4.1. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024- 2031
10.4.3. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031
10.4.4. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031
10.4.5. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.4.6. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts By End User, 2024-2031
10.5. Latin America
10.5.1. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
10.5.3. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031
10.5.4. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.5.5. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.5.6. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
10.6. Middle East & Africa
10.6.1. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
10.6.3. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031
10.6.4. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.6.5. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.6.6. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Pfizer Inc
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service Offerings
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Abbvie Inc.
11.2.3. Novartis AG
11.2.4. Amgen Inc.
11.2.5. Boehringer Ingelheim International GmbH.
11.2.6. Merck & Co Inc.
11.2.7. Sun Pharmaceutical Industries Ltd.
11.2.8. Teva Pharmaceuticals Industries Ltd.
11.2.9. AstraZeneca
11.2.10. Ampio Pharmaceuticals Inc.
11.2.11. Lilly
11.2.12. Zydus Group
11.2.13. Akorn, Incorporated
11.2.14. Daiichi Sankyo Company, Limited